ClinicalTrials.gg
RecruitingNCT07855341Updated Oct 16, 2026

Low-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty

A Phase 4 interventional study of Pericapsular nerve group (PENG) block and Bupivacaine in Pain, Postoperative, Muscle Weakness and Arthroplasty, Replacement, Hip, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 149 studies testing dexamethasone in Pain, Postoperative — 27 open to participants now, 31 under way, 2 of them phase 3. Dexamethasone · Pain, Postoperative.

Planned enrollment
99th of 149
60 · median 88
Started
2026
with 16 others
Phase 4
75 of 149
13 open now
Primary completion
2027-08
later than 26 of 30 live
Registered
147th of 149
by date
Lead sponsor
4 of 149
Ain Shams University

Among the 149 studies testing dexamethasone in Pain, Postoperative, this one is the 99th largest by planned enrollment, is one of 17 that started in 2026, is one of 75 in phase 4, reaches primary completion later than 26 of the 30 other live ones, and was the 147th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

27 of the 149 studies testing dexamethasone in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies testing dexamethasone in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare two regimens of the pericapsular nerve group (PENG) block, an ultrasound-guided injection of local anaesthetic targeting the nerves supplying the front of the hip joint, for postoperative pain relief and quadriceps muscle function in patients undergoing primary unilateral total hip arthroplasty under spinal anaesthesia.

The PENG block was originally proposed as a motor-sparing technique. However, the standard 20 mL volume can spread to the femoral nerve and cause quadriceps weakness. Reducing the injected volume may limit this spread and better preserve quadriceps strength, but smaller volumes risk shorter analgesic duration. Adding dexamethasone to a low-volume injection may compensate for the reduced volume.

The main questions this trial aims to answer are:

  • Does a low-volume PENG block (10 mL bupivacaine 0.25%) with 4 mg dexamethasone differ from a standard-volume PENG block (20 mL bupivacaine 0.25%) in the time to first rescue analgesia?
  • Does it differ in the incidence and severity of quadriceps weakness on the operated side?

Researchers will compare:

  • Group A (standard-volume PENG block): 20 mL bupivacaine 0.25%.
  • Group B (low-volume PENG block with dexamethasone): 5 mL bupivacaine 0.5% plus 4 mL normal saline plus 4 mg dexamethasone in 1 mL, giving 10 mL of bupivacaine 0.25%.

Participants will:

  • Receive spinal anaesthesia with heavy bupivacaine 0.5% and fentanyl.
  • Be randomly allocated to Group A or Group B using computer-generated random numbers.
  • Receive the PENG block under ultrasound guidance, performed by an anaesthesiologist expert in regional anaesthesia.
  • Receive intravenous paracetamol 1 g every 8 hours, with intravenous nalbuphine 5 mg as rescue analgesia when the pain score (NRS) is 4 or more.
  • Be assessed by an anaesthesiologist blinded to group allocation for pain scores at rest and on movement at 2, 6, 12 and 24 hours; quadriceps strength (MRC scale and straight leg raise) at 6, 12 and 24 hours compared with the preoperative baseline; total opioid consumption over the first 24 hours; and time to first ambulation within the first 24 hours.

The primary outcome is the time from completion of the PENG block to the first administration of rescue analgesia, recorded over the first 24 hours postoperatively. The study will be conducted at Ain Shams University Hospitals (El Demerdash Hospital) and will include 60 patients (30 per group), aged 50 to 70 years, ASA physical status I or II.

Read the detailed description

Background: Hip surgery is associated with moderate to severe postoperative pain that, if poorly controlled, delays mobilization, prolongs hospital stay, and increases complications in a frequently elderly population. Opioid-based analgesia is limited by dose-dependent adverse effects such as sedation, respiratory depression, nausea, vomiting, and constipation, particularly harmful in older patients. Peripheral nerve blocks provide effective analgesia, reduce opioid requirements, and are therefore central to enhanced recovery pathways after hip surgery.

The anterior hip capsule, the most densely innervated region of the joint, receives sensory articular branches from the femoral, obturator, and accessory obturator nerves. These arise cephalad to the inguinal ligament and are therefore not reliably captured by traditional infra-inguinal techniques such as the femoral nerve block or fascia iliaca compartment block.

The pericapsular nerve group (PENG) block was described in 2018 as an ultrasound-guided injection of local anaesthetic into the musculofascial plane between the psoas tendon and the iliopubic eminence, targeting these articular branches while theoretically sparing motor components. Meta-analyses of randomized trials confirm that the PENG block reduces postoperative opioid consumption and pain scores after hip surgery and facilitates positioning for neuraxial anaesthesia.

Despite being promoted as motor-sparing, the PENG block performed with the conventional 20 mL volume has been repeatedly associated with quadriceps weakness, reported in approximately 25% or more of patients, attributed to spread of local anaesthetic toward the femoral nerve proper within the fascia iliaca compartment. Cadaveric and imaging studies support a volume-dependent relationship: larger volumes increase femoral nerve staining, whereas smaller volumes reduce this risk. A cadaveric study estimated the maximum effective volume sparing the femoral nerve in 90% of specimens to be approximately 13.2 mL.

However, lowering the volume may shorten the duration of analgesia. Dexamethasone is among the most studied adjuvants for peripheral nerve blocks and can prolong analgesia of long-acting local anaesthetics while reducing postoperative nausea and vomiting; the analgesic benefit is largely achieved at a dose of approximately 4 mg.

A preliminary randomized trial reported that adding dexamethasone to ropivacaine for the PENG block prolonged postoperative analgesia compared with ropivacaine alone. The PENG block has also been shown to improve early functional recovery and reduce time to ambulation after hip arthroplasty. More recent work suggests that combining dexamethasone with a reduced local anaesthetic volume in PENG block can maintain analgesia while preserving quadriceps strength. However, the available evidence largely employs ropivacaine and time-to-first rescue as the principal endpoint; data on a bupivacaine-based low-volume regimen with dexamethasone, evaluated as a complete analgesic strategy, remain limited, which forms the rationale for the present study.

Aim: To compare the analgesic efficacy and quadriceps motor function of two PENG block regimens, a low-volume block (10 mL bupivacaine 0.25%) with 4 mg dexamethasone versus a standard-volume block (20 mL bupivacaine 0.25%), in patients undergoing primary unilateral total hip arthroplasty.

Study design and setting: Prospective, randomized, controlled clinical trial conducted at Ain Shams University Hospitals (El Demerdash Hospital). Study period: 1 year.

Randomization and blinding: Eligible patients who fulfil the inclusion criteria and consent to participate will be randomly allocated into two equal groups using computer-generated random numbers, such that patients with even numbers will be enrolled in Group A (standard-volume PENG block) and patients with odd numbers will be enrolled in Group B (low-volume PENG block with dexamethasone). The participants, the outcome assessors and the data analyst will be blinded to group allocation.

Study procedure:

  • History, clinical examination, and routine investigations (complete blood count, prothrombin time, partial thromboplastin time, random blood glucose) will be performed for all patients.
  • All patients will be fasting for 2 hours for clear fluids and 8 hours for heavy meals.
  • Standard monitoring (electrocardiography, non-invasive blood pressure, peripheral oxygen saturation) will be applied in the operating room and baseline readings recorded.
  • Under strict aseptic conditions, standard intrathecal anaesthesia will be administered using a 25-gauge spinal needle with 3-4 mL heavy bupivacaine 0.5% and 10-12.5 mcg fentanyl as additive.
  • In the event of hypotension, ephedrine 5-15 mg will be administered by slow titration.
  • Adequacy of spinal anaesthesia will be confirmed after 5 minutes by a cold sensation test and the modified Bromage scale; an adequate block will be considered if the sensory level is at or above the tenth thoracic dermatome (T10).
  • Study syringes will be prepared as follows: Group A (standard-volume PENG): 20 mL of bupivacaine 0.25% (50 mg). Group B (low-volume PENG with dexamethasone): 5 mL of bupivacaine 0.5% (25 mg) plus 4 mL of normal saline plus 4 mg dexamethasone in 1 mL, giving a total injectate volume of 10 mL of bupivacaine 0.25%.
  • An 80-100 mm, 22-gauge echogenic needle is advanced in-plane from lateral to medial into the plane between the psoas tendon and the iliopubic eminence, and the local anaesthetic is injected in increments after negative aspiration.
  • Correct injectate spread deep to the psoas tendon will be confirmed sonographically; failure to achieve appropriate spread will be recorded as a block failure.
  • Both blocks will be performed by an anaesthesiologist who is an expert in regional anaesthesia, under strict aseptic conditions and ultrasound guidance using a low-frequency curvilinear transducer (2-5 MHz; C60xp; SonoSite X-Porte; SonoSite Inc., Bothell, WA, USA).
  • The total bupivacaine dose (intrathecal plus block) will be kept within the recommended maximum of 2 mg/kg; the dose will be verified against body weight for each patient before injection.
  • All patients will receive the same multimodal analgesic regimen: intravenous paracetamol 1 g every 8 hours. Rescue analgesia will be intravenous nalbuphine 5 mg, administered slowly when the Numerical Rating Scale (NRS) pain score is 4 or more.
  • Intralipid emulsion 20% and full resuscitation facilities will be immediately available for management of local anaesthetic systemic toxicity.
  • All postoperative pain and motor assessments will be performed by a single anaesthesiologist who is blinded to group allocation and who is not involved in randomization, block performance, or intraoperative care.

Primary outcome: Time to first rescue analgesia, defined as the interval (in hours) from completion of the PENG block to the first administration of rescue analgesia (NRS 4 or more), recorded over the first 24 hours postoperatively.

Secondary outcomes:

  • Incidence and severity of quadriceps weakness on the operated side, assessed using the Medical Research Council (MRC) scale (0-5) together with the ability to perform a straight leg raise, at 6, 12 and 24 hours postoperatively compared with the preoperative baseline; clinically significant weakness defined as a reduction of one or more MRC grades or inability to perform a straight leg raise.
  • Postoperative pain assessed using the NRS (0-10) at rest and on movement at 2, 6, 12 and 24 hours postoperatively.
  • Total opioid consumption over the first 24 hours postoperatively.
  • Time to first ambulation within the first 24 hours.

Sample size: Using the Power Analysis and Sample Size (PASS) 11 program, results from a previous randomized trial showed that the PENG plus dexamethasone group demonstrated a significantly longer time to first rescue opioid analgesia (15.0 +/- 1.5 hours vs 9.1 +/- 1.7 hours). Based on these findings, a sample size of 30 patients per group achieves 100% power to reject the null hypothesis of equal means when the population mean difference is 5.9 hours with standard deviations of 1.5 for group 1 and 1.7 for group 2, and with a significance level (alpha) of 0.05 using a two-sided two-sample unequal-variance t-test.

Statistical analysis: Data will be coded and analyzed using the Statistical Package for the Social Sciences (SPSS) version 23. The primary outcome (time to first rescue analgesia) will be analyzed using Kaplan-Meier survival analysis with the log-rank test, and a Cox proportional-hazards model will be used to estimate the hazard ratio with 95% confidence interval. Quantitative parametric data will be presented as mean +/- standard deviation (SD) and compared using the unpaired Student t-test; non-parametric data as median (interquartile range, IQR) using the Mann-Whitney test; and qualitative data as number and percentage using the chi-square or Fisher exact test. Repeated measurements over time (NRS, MRC) will be analyzed using a linear mixed-effects model. Analyses will follow both the intention-to-treat and per-protocol principles, with block failure and conversion to general anaesthesia handled as protocol deviations and reported. A p-value \< 0.05 will be considered statistically significant.

Ethical considerations: The study will be conducted after approval from the Research Ethics Committee, Faculty of Medicine, Ain Shams University, and will be prospectively registered before enrolment of the first participant. Informed written consent will be obtained from all patients after a detailed explanation of the study procedure, including the off-label use of dexamethasone, the potential risks of the block (nerve injury, infection, local anaesthetic systemic toxicity), and the right to withdraw at any time without affecting their care. The privacy of participants and confidentiality of data will be guaranteed throughout all phases of the study.

03

Conditions studied

  • Pain, Postoperative
  • Muscle Weakness
  • Arthroplasty, Replacement, Hip

Keywords

  • PENG block
  • Pericapsular Nerve Group Block
  • Dexamethasone
  • Bupivacaine
  • Quadriceps Strength
  • Total Hip Arthroplasty
  • Nerve Block
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physical status .
  • Age 50-70 years.
  • Patients scheduled for elective primary unilateral total hip arthroplasty under spinal anaesthesia.
  • No sex predilection.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • Physical status or above.
  • to spinal anaesthesia (coagulopathy, local infection at injection site, raised intracranial pressure).
  • Revision or bilateral total hip arthroplasty.
  • Known allergy or to study drugs (bupivacaine, dexamethasone) or to any component of the multimodal analgesic regimen (paracetamol, nalbuphine).
  • Pre-existing neuromuscular disease, lower-limb motor deficit, or neuropathic pain syndrome.
  • Uncontrolled diabetes mellitus ( > 8% or fasting blood glucose > 180 mg/dL) or any contraindication to .
  • Cognitive impairment precluding pain and motor assessment, or chronic opioid use.
  • greater than 40 kg/m2 precluding adequate ultrasound visualization.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group B: Low-Volume PENG Block With Dexamethasone

    Patients will receive an ultrasound-guided PENG block with 5 mL of bupivacaine 0.5% (25 mg) plus 4 mL of normal saline plus 4 mg dexamethasone in 1 mL, giving a total injectate volume of 10 mL of bupivacaine 0.25%, after spinal anaesthesia.

    Procedure: Pericapsular nerve group (PENG) block · Drug: Bupivacaine · Drug: Dexamethasone

  • Active comparator
    Group A: Standard-Volume PENG Block

    Patients will receive an ultrasound-guided PENG block with 20 mL of bupivacaine 0.25% (50 mg) after spinal anaesthesia.

    Procedure: Pericapsular nerve group (PENG) block · Drug: Bupivacaine

Interventions

  • ProcedurePericapsular nerve group (PENG) block

    An 80-100 mm, 22-gauge echogenic needle is advanced in-plane from lateral to medial into the plane between the psoas tendon and the iliopubic eminence under ultrasound guidance using a low-frequency curvilinear transducer (2-5 MHz), and the local anaesthetic is injected in increments after negative aspiration. Correct injectate spread deep to the psoas tendon will be confirmed sonographically.

    Also known as: PENG block

  • Group A: 20 mL of bupivacaine 0.25% (50 mg). Group B: 5 mL of bupivacaine 0.5% (25 mg) diluted to a total injectate volume of 10 mL of bupivacaine 0.25%. Injected as the PENG block.

    Also known as: Marcaine

  • 4 mg dexamethasone in 1 mL added to the PENG block injectate in Group B (perineural).

    Also known as: Decadron

06

What researchers measure

Primary outcomes

  1. Time to First Rescue Analgesia

    The interval (in hours) from completion of the PENG block to the first administration of rescue analgesia (intravenous nalbuphine 5 mg, given when the Numerical Rating Scale pain score is 4 or more on a 0-10 scale, where 0 = no pain and 10 = worst possible pain).

    Time frame: From completion of the PENG block up to 24 hours postoperatively

Secondary outcomes

  1. Incidence and Severity of Quadriceps Weakness

    Quadriceps strength on the operated side assessed using the Medical Research Council (MRC) scale (0-5, where 0 = no contraction and 5 = normal power) together with the ability to perform a straight leg raise, compared with the preoperative baseline. Clinically significant weakness is defined as a reduction of one or more MRC grades or inability to perform a straight leg raise.

    Time frame: Preoperative baseline and at 6, 12 and 24 hours postoperatively

  2. Total Opioid Consumption

    Total dose (mg) of rescue intravenous nalbuphine administered over the first 24 hours postoperatively.

    Time frame: First 24 hours postoperatively

  3. Time to First Ambulation

    Time (in hours) to first ambulation.

    Time frame: Within the first 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Ain Shams University Hospitals (El Demerdash Hospital)
    Cairo, Cairo Governorate 00202, Egypt
    Recruiting
08

References and documents

Publications

  • Yu L, Shen X, Liu H. The efficacy of pericapsular nerve group block for postoperative analgesia in patients undergoing hip surgery: A systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2023 Feb 24;10:1084532. doi: 10.3389/fmed.2023.1084532. eCollection 2023. PubMed 36910500 ↗
  • Aliste J, Layera S, Bravo D, Jara A, Munoz G, Barrientos C, Wulf R, Branez J, Finlayson RJ, Tran Q. Randomized comparison between pericapsular nerve group (PENG) block and suprainguinal fascia iliaca block for total hip arthroplasty. Reg Anesth Pain Med. 2021 Oct;46(10):874-878. doi: 10.1136/rapm-2021-102997. Epub 2021 Jul 20. PubMed 34290085 ↗
  • Balasubramaniam A, Kumar Naggaih S, Tarigonda S, Madhusudhana R. Ultrasound-Guided Pericapsular Nerve Group Block for Hip Surgery: A Randomized Controlled Trial Study Comparing Ropivacaine and Ropivacaine With Dexamethasone. Cureus. 2023 Jan 27;15(1):e34261. doi: 10.7759/cureus.34261. eCollection 2023 Jan. PubMed 36855475 ↗
  • Reysner T, Kowalski G, Mularski A, Pyszczorska M, Grochowicka M, Perek A, Daroszewski P, Reysner M. Perineural dexamethasone effectively prolongs anaesthesic block duration in total hip arthroplasty, reduces opioid consumption, and does not compromise motor function, nerve integrity, or glycaemic control. Int Orthop. 2025 Aug;49(8):1791-1799. doi: 10.1007/s00264-025-06578-1. Epub 2025 Jun 11. PubMed 40498110 ↗
  • Reysner T, Neumann-Podczaska A, Pietraszek P, Mularski A, Kowalski G, Daroszewski P, Reysner M. Reduced Ropivacaine Volume with Perineural Dexamethasone in PENG Block for Total Hip Arthroplasty: A Randomized Controlled Trial. J Clin Med. 2025 Dec 9;14(24):8722. doi: 10.3390/jcm14248722. PubMed 41464623 ↗
  • Zufferey PJ, Chaux R, Lachaud PA, Capdevila X, Lanoiselee J, Ollier E. Dose-response relationships of intravenous and perineural dexamethasone as adjuvants to peripheral nerve blocks: a systematic review and model-based network meta-analysis. Br J Anaesth. 2024 May;132(5):1122-1132. doi: 10.1016/j.bja.2023.12.021. Epub 2024 Jan 27. PubMed 38281844 ↗
  • Kim JY, Kim J, Kim DH, Han DW, Kim SH, Kim D, Chung S, Yu S, Lee UY, Park HJ. Anatomical and Radiological Assessments of Injectate Spread Stratified by the Volume of the Pericapsular Nerve Group Block. Anesth Analg. 2023 Mar 1;136(3):597-604. doi: 10.1213/ANE.0000000000006364. Epub 2023 Feb 17. PubMed 36727847 ↗
  • Leurcharusmee P, Kantakam P, Intasuwan P, Malatong Y, Maikong N, Navic P, Kitcharanant N, Mahakkanukrauh P, Tran Q. Cadaveric study investigating the femoral nerve-sparing volume for pericapsular nerve group (PENG) block. Reg Anesth Pain Med. 2023 Nov;48(11):549-552. doi: 10.1136/rapm-2023-104419. Epub 2023 Apr 7. PubMed 37028817 ↗
  • Yeoh SR, Chou Y, Chan SM, Hou JD, Lin JA. Pericapsular Nerve Group Block and Iliopsoas Plane Block: A Scoping Review of Quadriceps Weakness after Two Proclaimed Motor-Sparing Hip Blocks. Healthcare (Basel). 2022 Aug 18;10(8):1565. doi: 10.3390/healthcare10081565. PubMed 36011222 ↗
  • Giron-Arango L, Peng PWH, Chin KJ, Brull R, Perlas A. Pericapsular Nerve Group (PENG) Block for Hip Fracture. Reg Anesth Pain Med. 2018 Nov;43(8):859-863. doi: 10.1097/AAP.0000000000000847. PubMed 30063657 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results will be made available upon reasonable request to the principal investigator.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 6 months after publication of the primary results, for a period of 3 years.

Access criteria: Requests from qualified researchers with a methodologically sound proposal, subject to approval by the principal investigator and the Research Ethics Committee, Faculty of Medicine, Ain Shams University, and a signed data access agreement.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 10 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Oct 15, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Sep 14, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
Ain Shams University Hospitals (El Demerdash Hospital) is now Recruiting
Oct 16, 2026
Title
Low-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty
Oct 5, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    Ain Shams University Hospitals (El Demerdash Hospital) is now Recruiting
    + 1 other change: date precision
  2. Oct 5, 2026
    Title Low-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty
    + 2 other changes: verification date and description
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855341
Responsible party
Mohamed Farag Mohamed Morsi (Assistant Lecturer of Anesthesia, Intensive Care Unit and Pain Management., Ain Shams University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 15, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Sep 14, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Mohamed F Morsi, M.B., B.Ch., M.Sc.
Contact
MohamedMorsi@med.asu.edu.eg
+201116618163
Mohamed F Morsi, M.B., B.Ch., M.Sc.
principal investigator · Faculty of Medicine, Ain Shams University
Azza A AbdelAleem, MD
study director · Faculty of Medicine, Ain Shams University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion